Work

Phase 1 trial of KT‐333, a STAT3 degrader, in patients with relapsed or refractory lymphomas, large granular lymphocytic leukemia and solid tumors

Year: 2023

Type: article

Abstract: heterobifunctional degraders for targeting previously undruggable targets. It is projected that higher doses of KT-333 will achieve the predicted degradation profile in tumors that may translate into clinical benefit in patients with STAT3-dependent T cell malignancies.

Source: Hematological Oncology

DOI: 10.1002/hon.3164_424

Authors: S. Smith, A. Olszewski, A. N. Starodub, D. A. Stevens, T. Feldman, P. Porcu, Z. Epstein‐Peterson, A. Huen, L. Pinter‐Brown, A. Mattour, R. Perea, A. Gollerkeri, J. Dey, C. Klaus, S. Agarwal, J. Gollob, A. Shastri

Institutions: Seattle Cancer Care Alliance, University of Washington, Rhode Island Hospital, Lifespan, Christ Hospital, Norton Healthcare, Hackensack University Medical Center, Thomas Jefferson University, Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, University of California, Irvine, UC Irvine Chao Family Comprehensive Cancer Center, Henry Ford Health, Montefiore Medical Center

Language: English

Topic: Protein Degradation and Inhibitors

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4379979696

FWCI: 0.178

Cites:

Cited by: 2

Related to: 10